Last edition
News about "Matchpoint Therapeutics "
Matchpoint, Novartis Partner to Develop Oral Inhibitors for Multiple Inflammatory Diseases
Matchpoint Therapeutics has entered into an exclusive option and license agreement with Novartis to develop and commercialise oral covalent inhibitors for multiple inflammatory diseases.
Matchpoint Therapeutics | 28/07/2025 | By Dineshwori | 114
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members